Enliven Therapeutics, Inc.
ELVN
Revenue
0.00
0.000.00%
-Assets
327.04M
▼-15.73M▼-4.59%
3 Months ChangeLiabilities
22.11M
▼-2.95M▼-11.79%
3 Months ChangeFree Cash Flow
-23.38M
▼-2.51M▼-12.00%
12 Months ChangeRevenue/Cost Of Revenue
Revenue
Cost Of Revenue
Loading...
| Date | Revenue | Cost Of Revenue |
|---|---|---|
Net Profit/Loss
Net Profit/Loss
Baseline
Loading...
| Date | Net Profit/Loss |
|---|---|
Assets/Liabilities
Assets
Liabilities
Loading...
| Date | Assets | Liabilities |
|---|---|---|
Cash Flows
Operating (Cash Flow)
Investing (Cash Flow)
Financing (Cash Flow)
Free Cash Flow
Loading...
| Date | Operating (Cash Flow) | Investing (Cash Flow) | Financing (Cash Flow) | Free Cash Flow |
|---|---|---|---|---|
EPS
EPS (Diluted)
Loading...
| Date | EPS | EPS (Diluted) |
|---|---|---|
Outstanding Shares
Loading...
| Date | Outstanding Shares |
|---|---|
Recent 8-K/10-Q Filings
2024-08-13
Form 10-Q
ID: 0000950170-24-096239
2024-08-13
Form 8-K
ID: 0000950170-24-096204
2024-06-18
Form 8-K
ID: 0001193125-24-163507
2024-05-14
Form 10-Q
ID: 0000950170-24-059573
2024-05-14
Form 8-K
ID: 0000950170-24-059544
2024-04-11
Form 8-K
ID: 0001193125-24-092522
2024-04-09
Form 8-K
ID: 0001193125-24-090821
2024-03-19
Form 8-K
ID: 0001193125-24-070839
2024-03-14
Form 8-K
ID: 0000950170-24-031482
2023-11-09
Form 10-Q
ID: 0000950170-23-062080